Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma

doi:10.1097/MD.0000000000009249

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/31723

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31723

题名:	Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
作者:	Kuo, Hsing-Tao Que, Jenny Lin, Li-Ching Yang, Ching-Chieh Koay, Lok-Beng Lin, Chia-Hui
贡献者:	Chia Nan Univ Pharm & Sci, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Internal Med, Div Hepatol,Chi Mei Med Ctr Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chung Hwa Univ Med Technol, Dept Optometry Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management
关键词:	cyberknife stereotactic body radiation therapy hepatocellular carcinoma tumor size
日期:	2017-12
上传时间:	2018-11-30 15:54:16 (UTC+8)
出版者:	Lippincott Williams & Wilkins
摘要:	Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT. Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (<= 4cm), intermediate-sized (>4-<10cm), and large (>= 10cm) tumors. Treatment outcomes, prognoses, and safety at each tumor size were compared and analyzed. A total of 52 patients with small tumors, 55 with intermediate tumors, and 34 patients with large tumors were retrospectively analyzed with a median follow-up of 16 months. Objective responses were achieved at 96.15%, 90.90%, and 76.47% for small, intermediate, and large tumors, respectively (P <= .0001) and the 3-year local control rates were 97.85%, 71.99%, and 82.14%, respectively (P=.0035). The 3-year overall survival rates were 50.26%, 45.29%, and 33.38% for small, intermediate, and large tumors, respectively (P=.3757). No significant differences were found in overall-survival, intra-hepatic recurrence free survival, disease-progression free survival, or distant metastasis-free survival. SBRT offers the best effective local control rate and response rate for small HCCs. However, tumor size did not significantly affect the overall survival rate, intra-hepatic recurrence free rate, or disease-progression free rate.
關聯:	Medicine, v.96, n.50, e9249
显示于类别:	[Dept. of Senior Service and Health Management] Periodical Articles [Dept. of Hospital and Health (including master's program)] Periodical Articles

文件中的档案:

档案	描述	大小	格式	浏览次数
00005792-201712150-00110.pdf		344Kb	Adobe PDF	0	检视/开启
index.html		0Kb	HTML	2271	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....